NSE: MARKSANS | BSE: 524404

Mid-range Performer

Download real time

252.55 5.50 (2.23%)

29.59% Fall from 52W High

1.0M NSE+BSE Volume

NSE 27 Jun, 2025 3:31 PM (IST)

11,444.6

Market Cap

High in industry

1.3

Beta 1Year

Very High Volatility

Marksans Pharma Ltd. share price target and research reports

Name: Latest research reports of Marksans Pharma Ltd. authored by Centrum Broking and published by - Trendlyne research reports.
Item: Marksans Pharma Ltd.
Rating: 3
Author: Centrum Broking

Latest analyst research reports with target prices and PDF download for MARKSANS, BSE:524404 Marksans Pharma Ltd.

Marksans Pharma Ltd.

27 Nov 2017, 12:00AM

252.55

2.23%

Marksans Pharma

Hold: Marksans Pharma Ltd.

Centrum Broking

Source: Bloomberg, Centrum Research, *as on 17h November 2017 Recommendation and key risks: We have revised our FY18E and FY19E EPS downwards by 14% and 7% respectively in view of forex losses and increase in crude based raw material prices. We downgrade MPL to Hold from Buy rating, with a TP of Rs45 based on 18x March'19 EPS of Rs2.5, and a 10.7% upside from CMP. Key positive upsides would be additional ANDA approvals from US FDA and key...

Marksans Pharma Ltd. has gained 55.86% in the last 1 Year

Marksans Pharma Ltd.

30 Sep 2016

252.55

2.23%

Marksans Pharma

Buy: Marksans Pharma Ltd.

Dynamic Levels

Marksans R&D; capabilities include dossier development, chemical synthesis, process optimization, formulation development, analytical development and conducting stability studies. The company has a team of over 50 experienced scientists specializing in formulation development and analytical development. The conpany has possessed end-to-end capabilities from Lab scale development to Pilot scale up and from commercializing the product for large...

Marksans Pharma Ltd. is trading below its 150 day SMA of 253.0

Marksans Pharma Ltd.

30 Jun 2015

252.55

2.23%

Marksans Pharma Ltd: Marksans Pharma acquires US based Time-Cap Labs Inc (Jun 30, 2015)

Buy: Marksans Pharma Ltd.

Karvy

Marksans Pharma has acquired US based Time-Cap Labs Inc in a transaction was valued at USD 28 mn. Time-Cap Laboratories, Inc is a New York based solid dosage tablet manufacturer synergies arise as it seeks to grow its presence in USA leveraging the manufacturing and packaging facilities of Time-cap, the brand equity of its products and distribution value chain. Time-cap has revenues of USD 30 mn per year and EBITDA of USD 4 mn and is a debt free company

Marksans Pharma Ltd. has gained 55.86% in the last 1 Year

Marksans Pharma Ltd.

01 Jun 2015

252.55

2.23%

Marksans Pharma Ltd: Q4FY15 Results First Cut - Momentum Continues in Top and Bo... (Jun 01, 2015)

Marksans Pharma Ltd.

Karvy

The company reported revenue growth of 8.9% for Q4FY15 over Q4FY14 and annual revenue reported a growth of 26.4% for FY15 over FY14.The company's Europe & UK segment reported growth of 25.7% while the US & North America reported growth of 65.3%. The improved product mix is reflected in operating margins which to 23.2% from 19.2% in FY14

Marksans Pharma Ltd. has gained 55.86% in the last 1 Year

Marksans Pharma Ltd.

14 Apr 2015

252.55

2.23%

Marksans Pharma

Marksans Pharma Ltd.

ICICI Securities Limited

Marksans Pharma Ltd. is trading above its 100 day SMA of 231.8

Marksans Pharma Ltd.

13 Feb 2015

252.55

2.23%

Marksans Pharma Ltd_Q3 Results Review (Feb 13, 2015)

Buy: Marksans Pharma Ltd.

Target

Karvy

Marksans Pharma: Strong growth continues; Target revised upwardsMarksans Pharma is a finished dosage producing company (with increasing focus on soft gelatine dosage manufacturing) and with subsidiaries in UK and Australasia operating in OTC and Rx. It has manufacturing facilities in Goa (USFDA, UKMHRA and TGA approved) and Southport, UK (UKMHRA).

Marksans Pharma Ltd. has gained 55.86% in the last 1 Year

Marksans Pharma Ltd.

07 Feb 2015

252.55

2.23%

Marksans Pharma Ltd 3Q FY15 First Cut (Feb 07, 2015)

Marksans Pharma Ltd.

Karvy

Marksans consolidated revenue up by 32.2% YoY and PAT up by 37.6% YoY in nine months of FY15. EBITDA margins at 23.35% for the 9 month period have grown at 50.8% YoY and a PAT growth at 13.5%. The company's US formulations segment reported revenue growth at 81.3% and reported revenues of Rs.120 crore for the nine month period

Marksans Pharma Ltd. has gained 55.86% in the last 1 Year

Marksans Pharma Ltd.

21 Jan 2015

252.55

2.23%

Marksans Pharma Ltd (Jan 21, 2015)

Buy: Marksans Pharma Ltd.

Karvy

Karvy Initiates coverage of Marksans with a Buy rating: We expect its softgel capabilities to improve its presence in USA. Clear of the debt overhang on the company financials and propelled by the subsidiaries return to growth, the company is expected to move into the next phase of growth and sustain its higher return ratios.

Marksans Pharma Ltd. is trading below its 150 day SMA of 253.0

Is Marksans Pharma Ltd. worth buying?

1398 Votes:

Buy 80.47%

Sell 10.09%

Hold 9.44%